Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genmab ASCHIX:GMABC +0.46%96 Debt-to-EBITDA is 6.22 as of Mar. 2026, which is 6120% above its 10-year median of 0.10. GuruFocus rates CHIX:GMABC with a GF Score™ of 96/100 and a GF Value™ of kr2,323.79 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 296 Biotechnology companies, Genmab AS ranks worse than 75% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Genmab AS's Debt-to-EBITDA or its related term are showing as below:
CHIX:GMABc'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.05 Med: 0.1 Max: 4.19
Current: 4.19
During the past 13 years, the highest Debt-to-EBITDA Ratio of Genmab AS was 4.19. The lowest was 0.05. And the median was 0.10.
CHIX:GMABc's Debt-to-EBITDA is ranked worse than 75% of 296
companies
in the Biotechnology industry
Industry Median: 1.185
vs CHIX:GMABc: 4.19
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Genmab AS Debt-to-EBITDA Related Terms
Genmab AS Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Genmab AS's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:GMABC vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Genmab AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Genmab AS's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Genmab AS (CHIX:GMABC) has a Debt-to-EBITDA of 6.22 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Genmab AS. This is 6120% above median its historical median of 0.10. Over the past decade, Genmab AS's Debt-to-EBITDA has ranged from 0.05 to 4.19. According to the industry distribution chart, Genmab AS ranks #222 out of 296 companies in the Biotechnology industry, placing it in the top 75%.
Is Genmab AS's Debt-to-EBITDA too high?
Genmab AS's current Debt-to-EBITDA of 6.22 is 6120% above median its 10-year median of 0.10. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 4.19. The Biotechnology industry median Debt-to-EBITDA is 1.19. Genmab AS's value of 6.22 is 424.9% above this industry median. Based on the distribution chart, Genmab AS ranks #222 out of 296 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genmab AS has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #222 out of 296 companies for Debt-to-EBITDA. This places Genmab AS in the lower half of its industry. The industry median Debt-to-EBITDA is 1.19. Genmab AS's value of 6.22 is 424.9% above this benchmark. Historically, Genmab AS's own Debt-to-EBITDA has ranged from 0.05 to 4.19 over the past decade. While the company's 10-year median is 0.10 vs. the industry median of 1.19, Genmab AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.19, based on 296 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current Debt-to-EBITDA of 6.22 is 424.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Genmab AS. For the Biotechnology industry, the median Debt-to-EBITDA is 1.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current Debt-to-EBITDA is 6.22, which is 6120% above median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2,323.79, compared to a current price of kr1,843.50 — trading 20.7% below its estimated fair value. The current Debt-to-EBITDA is 6.22, which is 6120% above median its 10-year median of 0.10 and 424.9% above the Biotechnology industry median of 1.19. Genmab AS's overall GF Score™ is 96/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Debt-to-EBITDA is 6.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (CHIX:GMABC) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of kr1,843.50 is trading 20.7% below its estimated GF Value™ of kr2,323.79.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for CHIX:GMABC:
Debt-to-EBITDA: 6.22 (6120% above median its 10-year median of 0.10)
GF Value™: kr2,323.79 vs. price of kr1,843.50 (20.7% below fair value)
Industry Position: 424.9% above the Biotechnology median (#222 of 296)
No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
96GF Score
Get the complete analysis for CHIX:GMABC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GMABC has been successfully added to your 
